NeuraxisNRXS
NRXS
About: Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
Employees: 21
0
Funds holding %
of 7,312 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
110% more capital invested
Capital invested by funds: $939K [Q4 2024] → $1.98M (+$1.04M) [Q1 2025]
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
8% more funds holding
Funds holding: 12 [Q4 2024] → 13 (+1) [Q1 2025]
7.01% more ownership
Funds ownership: 5.73% [Q4 2024] → 12.74% (+7.01%) [Q1 2025]
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$7
192%
upside
Avg. target
$7
192%
upside
High target
$7
192%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Craig-Hallum Chase Knickerbocker | 192%upside $7 | Buy Initiated | 16 Jun 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
3 weeks ago
NeurAxis Announces New Medical Policy Coverage with Two Health Insurers, Adding 700,000 Covered Lives
CARMEL, Ind., June 17, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), covering two health insurers, with approximately 700,000 total members in Connecticut and Massachusetts. This medical policy will bring our national total coverage for PENFS to roughly 53 million, with more decisions from major payers still pending.
Neutral
GlobeNewsWire
1 month ago
NeurAxis Announces Closing of $5.0 Million Registered Direct Offering
CARMEL, Ind., May 22, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced the closing of its previously announced registered direct offering of 1,538,461 shares of its common stock at a purchase price of $3.25 per share.
Neutral
GlobeNewsWire
1 month ago
NeurAxis Announces $5.0 Million Registered Direct Offering
CARMEL, Ind., May 21, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1,538,461 shares of its common stock at a purchase price of $3.25 per share in a registered direct offering priced at the market under NYSE American rules.
Positive
Zacks Investment Research
1 month ago
NeurAxis Stock Gains Following Strong Q1 Earnings and FDA Milestones
NRXS posts strong first-quarter 2025 earnings with robust revenue growth and FDA milestones, driving stock gains as investors eye broader insurance coverage and market expansion.
Neutral
Seeking Alpha
1 month ago
NeurAxis, Inc. (NRXS) Q1 2025 Earnings Call Transcript
NeurAxis, Inc. (NYSE:NRXS ) Q1 2025 Earnings Conference Call May 12, 2025 9:00 AM ET Company Participants Ben Shamsian - IR Brian Carrico - President, CEO & Director Tim Henrichs - CFO Brian Carrico - President, CEO & Director Conference Call Participants Operator Good day, and thank you for standing by. Welcome to the NeurAxis First Quarter 2025 Results and Update Call.
Neutral
GlobeNewsWire
1 month ago
NeurAxis Reports Strong First Quarter 2025 Financial Results Driven by a 39% Growth in Revenues
CARMEL, Ind., May 12, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the first quarter 2025 for the period ended March 31, 2025.
Neutral
GlobeNewsWire
2 months ago
NeurAxis to Host First Quarter 2025 Results and Business Update Call on Monday, May 12, 2025
Financial results to be released before market open; Conference call to be conducted at 9:00 a.m. Eastern Time Financial results to be released before market open; Conference call to be conducted at 9:00 a.m. Eastern Time
Positive
Zacks Investment Research
3 months ago
NeurAxis Stock Gains Post Q4 Earnings and Revenue Growth
NRXS records strong revenue growth, expanded insurance coverage and new FDA clearances in fourth-quarter 2024.
Neutral
Seeking Alpha
3 months ago
NeurAxis, Inc. (NRXS) Q4 2024 Earnings Call Transcript
NeurAxis, Inc. (NYSE:NRXS ) Q4 2024 Earnings Conference Call March 20, 2025 9:00 AM ET Company Participants Ben Shamsian - Investor Relations Brian Carrico - Chief Executive Officer Tim Henrichs - Chief Financial Officer Operator Good day, and thank you for standing by. Welcome to the NeurAxis' Fourth Quarter 2024 Financial Results Conference Call.
Neutral
GlobeNewsWire
3 months ago
NeurAxis Reports Strong Fourth Quarter 2024 Financial Results Driven by a 43% Increase in Revenues
CARMEL, Ind., March 20, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the fourth quarter and fiscal year 2024 for the period ended December 31, 2024.
Charts implemented using Lightweight Charts™